StemRIM Company Description

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.

The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis.

It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy.

The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.

StemRIM

Country	Japan
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	45
CEO	Masatsune Okajima

Contact Details

Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan
Phone	81 72 648 7152
Website	stemrim.com

Stock Details

Ticker Symbol	4599
Exchange	Tokyo Stock Exchange
Fiscal Year	August - July
Reporting Currency	JPY
ISIN Number	JP3399690001
SIC Code	2836

Key Executives

Name	Position
Masatsune Okajima	Chief Executive Officer